Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
Taymeyah Al‐Toubah, Eleonora Pellè, Tiffany Valone, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 20, Iss. 1, pp. 29-36
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Dwight H. Owen, Brooke Benner, Lai Wei, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 4, pp. 731-741
Open Access | Times Cited: 24
Update in the management of gastroenteropancreatic neuroendocrine tumors
Andrew J. H. Sedlack, Diana Grace Varghese, Amirkia Naimian, et al.
Cancer (2024) Vol. 130, Iss. 18, pp. 3090-3105
Closed Access | Times Cited: 5
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
Arianna Zappi, Irene Persano, Linda Galvani, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 717-717
Open Access | Times Cited: 13
Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients
Jonathan Strosberg, Taymeyah Al‐Toubah, Ghassan El‐Haddad, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 3, pp. 340-348
Open Access | Times Cited: 4
Chemotherapy in Neuroendocrine Tumors
Satya Das, Taymeyah Al‐Toubah, Jonathan Strosberg
Cancers (2021) Vol. 13, Iss. 19, pp. 4872-4872
Open Access | Times Cited: 24
Outcomes of capecitabine plus temozolomide combination therapy in patients with advanced or metastatic pancreatic neuroendocrine tumors: a retrospective observational single-center study
Yukiko Hibino, Susumu Hijioka, Chigusa Morizane, et al.
International Journal of Clinical Oncology (2025)
Open Access
Research Progress of circRNAs in Glioblastoma
Xu Guo, Haozhe Piao
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 19
Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease
Erica S. Alexander, Etay Ziv
Cancers (2023) Vol. 15, Iss. 8, pp. 2249-2249
Open Access | Times Cited: 7
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
Jorge Hernando, María Roca-Herrera, Alejandro García‐Álvarez, et al.
European Journal of Cancer (2023) Vol. 188, pp. 39-48
Open Access | Times Cited: 7
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
Çağlar Ünal, Abdulmunir Azizy, Senem Karabulut, et al.
The Oncologist (2023) Vol. 28, Iss. 10, pp. 875-884
Open Access | Times Cited: 7
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
Maria Passhak, Mairéad G. McNamara, Richard Hubner, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101836-101836
Closed Access | Times Cited: 7
Is NETTER-2 a practice-changing trial?
Jonathan Strosberg, Mauro Cives
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 705-706
Closed Access | Times Cited: 2
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Siren Morken, Seppo W. Langer, Anna Sundlöv, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 12, pp. 1930-1939
Open Access | Times Cited: 6
Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate
Stephanie L. Pritzl, Yael Kusne, Þorvarður R. Hálfdánarson, et al.
Leukemia Research (2023) Vol. 136, pp. 107434-107434
Closed Access | Times Cited: 4
Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies
Simon April-Monn, Philipp Kirchner, Katharina Detjen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors
Maria Ingenerf, Christoph J. Auernhammer, Roberto Lorbeer, et al.
Radiology and Oncology (2024) Vol. 58, Iss. 2, pp. 196-205
Open Access | Times Cited: 1
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
Jonathan M. Loree, David Chan, Jennifer Lim, et al.
JAMA Oncology (2024)
Closed Access | Times Cited: 1
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
Taymeyah Al‐Toubah, Jonathan Strosberg, Julie Hallanger‐Johnson, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Sriram Gubbi, Namrata Vijayvergia, Jian Yu, et al.
Hormone and Metabolic Research (2022) Vol. 54, Iss. 12, pp. 795-812
Open Access | Times Cited: 5
S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial
Yihebali Chi, Lijie Song, Weili Liu, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101667-101667
Open Access | Times Cited: 5
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors
İzzet Doğan, Didem Taştekin, Senem Karabulut, et al.
Journal of Digestive Diseases (2022) Vol. 23, Iss. 8-9, pp. 493-499
Closed Access | Times Cited: 4
Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies
Aurel Perren, Simon April-Monn, Katharina Detjen, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review
Dileep Kumar Reddy Regalla, Ojasvi Deep, Ravi Kumar Paluri
Chinese Clinical Oncology (2023) Vol. 12, Iss. 6, pp. 67-67
Open Access | Times Cited: 2
Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms
Robin Park, Manik Amin, Nikolaos A. Trikalinos
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 7
Closed Access | Times Cited: 3
In Defense of Neuroendocrine Tumor Trials
Jonathan Strosberg, Taymeyah Al‐Toubah, Mauro Cives
JAMA Oncology (2023) Vol. 9, Iss. 10, pp. 1463-1463
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top